Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age

Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases

“…In the Austrian group, no significant differences in ORR, OS, and toxicity were seen in patients with or without reduced doses of NPLD. 30 In these studies, LVEF slightly decreased during therapy, but no significant changes from baseline to the end of chemotherapy were observed, neither in patients with nor without concurrent cardiac diseases. The occurrence rates of cardiac events differed.…”

“…[25][26][27] Some smaller studies that examined the use of NPLD as a replacement for conventional doxorubicin as a component of the R-CHOP regimen showed the promising tolerability and efficacy of this regimen in elderly patients. [28][29][30][31][32][33] Of note, in prospective studies, patients with previous chemo-or radiotherapy, myocardial infarction during the previous 12 months and reduced LVEF < 45% 32 or < 50% and significant comorbidities 29 were excluded. Gimeno et al 31 administered NPLD in reduced dosages of 30 mg/m 2 in frail elderly patients with comorbidities, leading to a 2-year PFS and OS of 58% and 70%, respectively, but these results included patients with NHLs other than DLBCL.…”

Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: A survey from Tyrolean hospitals

“…Th ere might be a role of bendamustine/rituximab in cases in the low/intermediate IPI group but cardiac disease in whom anthracyclines are contraindicated. As an alternative, liposomal doxorubicine may be a substitute for doxorubicine in the CHOP regimen for cardially compromised patients, without loss of therapeutic effi cacy [24].…”

Komorbiditätsorientierte Onkologie – ein Überblick

“…Heintel et al untersuchten kürzlich 37 PatientInnen mit Non-Hodkin Lymphom höheren Alters oder vorbestehender kardialer Schädigung, welche mit einem nichtpegyliertem liposomalen Doxorubicin behandelt wurden. In dieser Studie kam es weder zum Auftreten einer klinisch manifesten Kardiotoxizität noch zum Auftreten kardialer Ereignisse [119]. Die Implementierung liposomaler Anthrazykline ermöglicht zum einen die Th erapie älterer Patienten, zum anderen die Kombinationstherapie mit anderen, potentiell kardiotoxischen Substanzen wie zum Beispiel Trastuzumab [120].…”